1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Opportunity Analyzer: Bladder Cancer - Opportunity Analysis and Forecasts to 2017

Opportunity Analyzer: Bladder Cancer - Opportunity Analysis and Forecasts to 2017

  • December 2015
  • 191 pages
  • ID: 3716477
In this report:
ATEZOLIZUMAB IS PROJECTED TO GAIN ##% OF THE PATIENT SHARE IN THE PLATINUM-RELAPSED/REFRACTORY METASTATIC DISEASE SETTING BY 2017, RESULTING IN TOTAL SALES OF $##.##M.
THE MAJORITY OF THIS GROWTH IS EXPECTED TO COME FROM THE US, WITH SALES RISING CONSIDERABLY, TO ACCOUNT FOR ##.##% OF SALES IN THE ##MM BY 2017.

Summary

Table of Contents

Search Inside

Opportunity Analyzer: Bladder Cancer - Opportunity Analysis and Forecasts to 2017

Brief

The bladder cancer market has remained largely unchanged in the past 10-20 years. However, meaningful expansion is expected starting in 2016, with the introduction of various additional therapies that are estimated to fuel market increase. Additionally, bladder cancer has a strong early-stage pipeline that will contribute to market increase beyond the forecast period of 2012-2017. Currently, the bladder cancer market is dominated by generic chemotherapy and immunotherapy. Though initially effective, toxicity and lack of clinical efficacy in improving global survival have left the door open for more tolerable and effective drugs to be developed. In the past, bladder cancer has not been an area of focus for pharmaceutical companies, but that is quickly changing as more companies focus on the bladder cancer market, recognizing the high level of unmet need and relatively clear regulatory path. During the forecast period, the market landscape will begin to change dramatically with the introduction of targeted immunotherapies. These drugs will provide much-needed alternatives to bladder cancer patients who have not benefitted from traditional treatments.

Key Findings

Key questions & answers

- The bladder cancer market is poised to undergo quick expansion during the forecast period and beyond. What are the principal drivers of this expansion? What are the principal barriers that could dampen this expansion?

- The bladder cancer market is plagued by the presence of high unmet needs not addressed by current treatments. What are the principal unmet needs in this sector? Will the drugs under development fulfil the unmet needs of the bladder cancer market?

- The current bladder cancer market is highly generic. How will the introduction of targeted immunotherapies, containing the much-anticipated PD-1/PD-L1 class of immune checkpoint inhibitors, change the market landscape?

Main highlights

- The principal driver of the quick expansion of the bladder market will be the launch of different highly anticipated drugs into the sector starting in 2016.

- The second biggest driver will be the forecast increase in number of incident cases in bladder cancer.

- To gain approval, it is vitally for companies to demonstrate efficacy in delaying recurrence, but not necessarily improvement in global survival. Thus, the bar for approval in bladder cancer is low.

- In the outlook, corporations will have to differentiate their drugs from others in the same class in order to successfully compete for patient share.

- The number of pipeline agents being developed by small to mid-sized companies represents an opportunity for big pharma to enter this highly lucrative market through licensing and marketing partnerships.

Overview

- Overview of bladder cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

- Annualized bladder cancer therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 and estimate for 5 years to 2017.

- Key topics covered include tactical competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the bladder cancer therapeutics market.

- Pipeline analysis: exhaustive data split across distinct phases, emerging novel trends under development, and in-depth analysis of late-stage pipeline drugs.

- Analysis of the current and future market competition in the overall bladder cancer therapeutics market. Insightful review of the top industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Great reasons to purchase

The market research will enable you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most strong pipeline. Additionally a list of acquisition targets included in the pipeline product company list.

- Develop strategic management by understanding the trends shaping and driving the overall bladder cancer therapeutics market.

- Drive revenues by understanding the main trends, innovative products and technologies, market segments, and firms likely to impact the overall bladder cancer therapeutics market in future.

- Specified effective sales and marketing strategies by understanding the challenging landscape and by analysing the performance of different competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a ambitious advantage.

- Track drug sales in the overall bladder cancer therapeutics market from 2012-2017.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and tactical partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Amrita helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Global Bladder Cancer Partnering 2010 to 2017

Global Bladder Cancer Partnering 2010 to 2017

  • $ 1495
  • Industry report
  • November 2017
  • by Currentpartnering

The Global Bladder Cancer Partnering since 2010 report provides understanding and access to partnering deals and agreements entered into by the world’s leading healthcare companies.• Trends in partnering ...

Non Muscle Invasive Bladder Cancer - Pipeline Insight, 2017

Non Muscle Invasive Bladder Cancer - Pipeline Insight, 2017

  • $ 1250
  • Industry report
  • November 2017
  • by Delve Insight

DelveInsight’s, “Non Muscle Invasive Bladder Cancer-Pipeline Insights, 2017”, report provides comprehensive insights of the ongoing therapeutic research and development across Non Muscle Invasive ...

Bladder Cancer Global Clinical Trials Review, H1, 2017

Clinical Research in Bladder Cancer in H1, 2017

  • $ 2500
  • Industry report
  • April 2017
  • by GlobalData

Bladder Cancer Global Clinical Trials Review, H1, 2017SummaryGlobalData’s clinical trial report, “Bladder Cancer Global Clinical Trials Review, H1, 2017" provides an overview of Bladder Cancer clinical ...


Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in the Netherlands

  • January 2018
    8 pages
  • Cancer  

  • Netherlands  

    Germany  

View report >

Cancer Statistics in the US

  • December 2017
    113 pages
  • Cancer  

  • United States  

    North America  

View report >

Cancer and Lymphoma Statistics in the US

  • November 2017
    37 pages
  • Cancer  

    Lymphoma  

    Lung Cancer  

  • United States  

View report >

ref:plp2015

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.